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Abstract. ln highly endemic settings for hepatitis B virus (HBV) infection such as Senegal, access to HBV prevention
and care is rapidly evolving. ln this context, all medical practitioners should have baseline knowledge on HBV infection and
promote access to vaccination, screening, and care. A knowledge and attitudes survey on HBV infection was conducted
among a randomly selected sample of medical practitioners in Senegal. Participants were asked to fill-out a questionnaire
on the HBV epidemiology, prevention, and treatment, A 60-item knowledge score was computed; the lower quartile of the
observed score was used to define poor knowledge. Factors associated with poor knowledge were assessed using a
logistic regression model. A tolal of 127 medlcal practltioners completed the questionnaire. Only 14 (11,0%) participañts
knewthat HBVvaccine could besafely administered to pregnantwomen and 65 (51 .2%)to newborns. Olderpractitioners
þ 40 ygqrs) as well as general practitioners (compared with specialists) were more likely to have a poor knowledge score
with odds ratios (ORs) of 3.1 (95% confidence interval [Cl] 1.0-9.2) and 2.6 (95% C|1.0-7.3), respectivety. Practitioners
who declared not to recommend HBV screening frequently during their consultation were more likely to present a poor
knowledge score [OR: 3.0; (95% Cl 1.1-8.2I. As universal HBV screening is being promoted in countries with endemic
HBV infection, our finding that poor screening attitudes were associated with a poor knowledge is of concern. There is a
need to raise awareness of medical practitioners in Senegal toward universal HBV screening and early vaccination of
newborns.
BACKGROUND
lnfection with hepatitis B virus (HBV) is highly endemic in
sub-Saharan Africa. ln Senegal, the prevalence of chronic
HBV infection ranges from 11 to 15% in adults.l-3 HBV in-
fection is a leading cause of liver disease and the most im-
portant risk factor for liver cancer in sub-saharan Africa.a'5
Although an effective vaccine against HBV infection is avail-
able since the early 80s, HBV vaccination as part of the ex-
panded program on immunization has only been introduced
since 2005 with several challenges. First, the vaccination
coverage remains low with only 46% of children presenting
serological protection against HBV (anti-HBs antibody titer
> 10 lU/mL) among 486 Senegalese hospitalized children.6,7
Second, the timing of administration is suboptimal: HBV
vaccination was first introduced as a combined vaccine (DTP-
HepB-Hib) with a first dose at 6 months limiting its efficacy
against mother-to-chiid transmission of HBV. Aside these
challenges, it takes decades for a preventive strategy based
on universal vaccination to reach its full effectiveness. ln the
meantime, thousands of chronically infected adults are in
need for screening and care. Although universal use of ef-
fective anti-HBVtherapy is still challenging, there are elements
supporting a future expanded access to these treatments. ln
Senegal, tenofovir is part of the recommended first-line anti-
retroviral therapy regimen for HIV-infected patients and could
become available for H|V-uninfected individuals in the near
future.
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Considering the parlicularly high burden of HBV in Senegal,
the management and the prevention of chronic hepatitis B
should not be restricted to a limited number of specialists. All
medical practitioners should indeed have basic knowledge on
HBV infection, should promote access to prevention through
vaccination and should encourage screening. Our aim was to
investigate knowledge and attitudes toward HBV infection
among medical practitioners from three urban areas in Senegal.
METHODS
Study population. Three major urban areas in Senegal
were selected for the present study: "Saint-Louis" in the
north of the country, Dakar; the economic and the adminis-
trative cap¡tal, and Ziguinchor in southern Senegal. These
three cities host university hospitals with the referral capacity
to manage patients with chronic HBV infection.
The study population was composed of certified medical
doctors (registered with a medical diplomathat allowed them to
practice medicine in their respective hospitals) from the public
sector, cunently in activity in thesethree urban areas during the
study period (August to December 2015). All primary to tertiary
health centers were mapped with their respective number of
medical practitioners in activity using a March 201 5 updated list
provided by the ministry of health. All medical doctors from
Saint-Louis and Ziguinchor were invited to participate. Con-
sidering the large number of practitioners in the urban area of
Daka¡ a sampling procedure was applied to randomly select a
representative group of medical doctors from the public health
sector, stratified at the level of health-care facilities. Of the nine
tertiary hospitals, two were selected to participate; Hôpital de
Fann and Hôpital Principal, Of the 15 health centers of primary
and secondary levels, four were selected. Two clinical monitors
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provided self-administered questionnaires to practitioners
working in medical units potentially involved in the care of HBV-
infected patients in the selected health-care facilities. Ques-
tionnaires were distributed to participating medical units and
collected back, once completed by medical doctors, afew days
later.
Data collection, The questionnaire administered in
French, the official language in Senegal, was divided in four
sections: sociodemographic and profess¡onal characteris-
tics of participants; epidemiology, natural history, and
clinical complications of HBV infection; knowledge and at-
titudes related to HBV screening and vaccination; and
knowledge on care and treatment of HBV infection. A list of
knowledge items considered as essential to medical doc-
tors was proposed in the three last sections based on a
consensus agreement between infectious disease and liver
diseases specialists from academic institutions in Senegal.
A knowledge score was then computed based on the sum of
correct answers to the 24 knowledge questions related to
HBV epidemiology/natural history/complications, preven-
tion, and treatment. One point was awarded for each correct
answer; each question had a unique or multiple answer
items for a total number of 60 items. lncorrect or missing
answers had a null value.
Statistical analysis. Characteristics of participants were
compared using Pearson's ¡2 test or Fisher's exact test for
categorical variables and Kruskall-Wallis test for continu-
ous variables. ln the aþsence of validate score to accurately
measure the knowledge of medical doctors toward HBV
infection, we arbitrarily define what was considered as a
poor knowledge in this particular population. Using as a
threshold the 25th percentile of the distribution of the
60-item score, the observed population served as its own
reference. A low knowledge score was thus defined as being
below the lower inter-quartile value of the observed score
distribution to identify a group of particularly uninformed
practitioners toward H BV infection and compare them to the
rest of the study population. An unconditional logistic re-
gression model was used to identify factors associated with
a low knowledge score including respondent characteris-
tics as well as their screening and preventive practices.
Variables that were statistically associated with a low
knowledge score with a P < 0.25 in univariable analyses
were selected for the multivariable model. The final model
was explored using a manual descending procedure and
taking into account potential confounders. A P < 0.05 was
considered statistically significant in the final model. Fac-
tors associated with a low knowledge score were presented
with their odds ratio (OR) and 95% confidence interval
(95% Cl). Allstatistical analyses were performed using SAS
software 9.2 (SAS lnstitute lnc. NC).
RESULTS
Of a total of 110 questionnaires distributed in Dakar, 75
(68.20/0) were completed, ln Saint-Louis and Ziguinchor, all
medical doctors surveyed completed the questionnaires with
22 and 3O forms returned, respectively.
The overall sample of respondents was thus composed of
127 medical doctors from the public sector working in these
three cities. Their median was 35 years of age (interquartile
range [QR]: 31-49) and their median time since medical
certification was 4 years (lQR: 1-9); 45 (35.4%)were general
practitioners and 82 (64.6%) specialists, including seven
gastroenterologists and 10 infectious disease specialists.
There were no significant differences in these demographic
and professional characteristics according to cities
(ïable 1).
Knowledge on HBV. The median value of the 60-item score
was 38 (lQR: 34-44), A low knowledge score (< 34 points)was
reported in 16 (21 .3%) pafticipants in Dakar, three (13.6%) in
Saint-Louis, and eight (26.7%) in Ziguinchor (P = 0.52). De-
tailed responses are reported in a supplementary table (Sup-
plemental Appendix'l).
HBV epidemiology, natural history and clinical
complications, Routes of transmission of HBV were rel-
atively well recognized with 84 (66.1%) medical doctors
giving correct responses to all four items related to the
routes of transmission. ln contrast, only 53 (41 .7o/ol par-
ticipants knew that the risk of HBV acquisition was linked to
age and 19 (15.0%) knew that the most at-risk period for
HBV acquisition was < 5 years of age. Only 2'1 (16.5%)
participants correctly responded to the eight items related
to HBV complications. Although liver cancer and cirrhosis
were identified as complications of HBV infection by 125
(98.4%) and 124 (97 .6%)participants, only 50 (39.4%) knew
that lung cancerwas not related to chronic HBV infection, ln
total, 20 (15.7%) practitioners correctly responded to the
five items related to liver cancer risk factors. Hepatitis C was
not thought to be related to liver cancer by 25 (19.7%)
participants and only 44 (34.6%) knew that hepatitis A was
not a risk factor for liver cancer.
HBV screening and vaccination. A correct answer to all
questions related to tests that should be part of the initial
assessment was provided by  0 (31 .5%) medical doctors,
Although 124 (97.60/o) participants knew that HBV infection
could be screened for, the availability of a rapid diagnostic
test was only known by 30 (23.6%) of them. HBV vaccine
was reported to have a proven efficacy by 121 (95.3%)
practitioners but only 48 (37.8%) knew that the vacc¡ne was
not linkedtoneurological disorders and 61 (48.0%) believed
that it could lead to infertility (60.0% in general practitioners
and 41.5% in specialists) (P = 0.04) Crable 2), Only 14
(11.0%) of participants believed that HBV vaccine could be
safely administered to pregnant women and 65 (51 .2%) lo
newborns.
HBV treatment. The existence of an efficient treatment
against chronic HBV infection was reported by 102 (80.3%)
participants. A correct answerto all items related to anti-HBV
treatments was provided by four (3.1 %) participants. The use
of lamivudine and tenofovir was reported as effic¡ent against
HBV by 65 (51.2%l and73 (57 .5%) participants, respectively.
A systematic anti-HBV treatment of all infected individuals
was proposed by 23 (18.1 %) practitioners while 101 (79.5%)
believed that treatment indications should rely on the as-
sessment of liver injury combined with biological markers. ln
case of HIV/IIBV coinfection, 68 (53.5%) practitioners esti-
mated that the treatment of HBV infection was needed
for all patients. Only 41 (32.3%) participants believed that
once initiated, the anti-HBV treatment was usually a lifelong
treatment.
Attitudes related to HBV screening and vaccination.
Screening of chronic HBV infection. Forty-six (36.2%)
practitioners stated that they never or only rarely proposed
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T¡eLe 1
Main characteristics of medical doctors by c¡ty (N = 127), Senegal, 201 5
39'l
Dakar (N 
= 
75) Salnt-Louls (N 
= 
22) Zigu¡nchor (N 
= 
30) P Total(N-127)
Age (median, üQRl)
Gender
Women
Men
Type of facility
Referal hospital
Primary care clinic
Medical activity
General pract¡t¡oners
Spec¡al¡sts-
Median number of years since
medical certificationl
Attended a lecture on HBV{
No
Yes
Source of information on HBV
ln¡t¡âl medical training
No
Yes
National guidelines
No
Yes
lnternet
No
Yes
Conferences
No
Yes
33 (30-38)
28
47
(37.3)
(62.7)
60 (80.0)
15 (20.0)
22 (29.3)
53 (70.7)
4 (1-8)l
3 (4.0)
72 (96.0)
55 (73.3)
20 (26.7)
19 (25.3)
56 (74.7)
55 (73.3)
20 (26.71
37 (31-46)
7 (31.8)
15 (68.2)
38 (32-50)
B (26.7)
22(73.31
35 (31-4s)
43 (33.9)
84 (66.1)
100 (78.7)
27|\21.3)
45 (35.4)
82 (64.6)
4 (1-e)
88 (69.3)
39 (30.7)
I (6.s)
119 (93.7)
14 (63.6)
I (36.4)
11 (50.0)
11 (50.0)
3 (1-1 1)
14 (63.6)
I (36.4)
22(73.31
B (26.7\
3 (10.0)
27 (e0.0)
28 (93.3)
2 (6.7)
6 (20.0)
24 (80.0)
21 (70.0)
e (30.0)
0.03
0.56
0.12
0.17
0.81
0.75
0.43
0.07
0.48
0.87
26 (86.7)
4 (13.3)
12 (40.0)
18 (60.0)
2 (1-e)
52 (6e.3)
23 (30.7)
2 (e.1)
(e0.e)20
18 (81 .8)
4 {18.2)
3 (13.6)
1e (86.4)
15 (68.2)
7 (31.8)
(22.0)
(78.0)
28
99
101 (79.5)
26(2o.5)
e1 (71.6)
36 (28.3)
IQR 
= 
inter quartile range
radlologist (/V 
= 
1), rhsumatolog¡st (N 
= 
l ).
1 Last m€dlcsl diplomathat allowôd them to practico modlclne as a general pract¡lioner or speclallst,
+ Pract¡t¡onersthat attended at least one dedicat€d Iectur€ on HBV infect¡on aftertheir lnltlal medical train¡ng.
HBVtesting to their patients. ln the hypothetical context of free
access to HBV screening, 105 {82.7%)medical doctors would
propose the test to all unvaccinated persons, whereas 22
(173%) would restrict it to high-risk populations (men who
have sex with men, blood product recipients, health profes-
sionals, and sex workers). A personal history of HBV screening
was reported by 101 (79.5%) medical doctors, whereas 91
(72.2%) declared usually advis¡ng their relatives to test
for HBV.
Anti-HBV vacc¡nation. Of the 126 participants, 90
(7 1.4%io) declared being personally vaccinated against H BV.
Medical doctors > 40 years were less likely to be vaccinated
(51.1%') compared with those 140 years (76.9) (P = 0.03). lf
confronted to children, 88 (69.3%) medical doctors stated
they usually checked their HBV vaccination status. Of
the 73 respondents reporting having children themselves,
57 (73.1Yo) declared that they were already vaccinated
against HBV.
Factors associated with a low HBV knowledge score. ln
multivariate analyses, older practitioners (> 40 years)as well
as general practitioners (compared with specialists) were
more likely to have a low knowledge score with ORs of 3,1
(95% Cl 1.0-9.2) and 2.6 (95% Cl1.0-7.3), respectively
fl-able 3). Practitioners who did not attend any lecture
dedicated to HBV infection after their initial medical train-
ing were also more likely to have a low knowledge score
IOR 6.0 (95% Cl 1.4-26.4)1. Finally, medical doctors who
declared not to recommend HBV screening frequently
during their consultation were more likely to present a low
knowledge score [OR 3.0 (95% Cl 1.1-8.2)]. The absence
of personal history of HBV screening or HBV vaccination
were not assoc¡ated with a low knowledge score among
these medical doctors with OR of 0.8 (95% Cl 0.3-2.3) and
1.1 (95% Cl 0.4-2.9), respectively.
DISCUSSION
The overall HBV-related knowledge of medical doctors in
urban Senegal in 2015 was relatively good although marked
differences were observed according to the specific themes
assessed. A good understanding of the epidemiology and
natural history of HBV infection was the rule. Our results
contrasts with the poor understanding of HBV infection usu-
ally reported among health-care workers in sub-Saharan
Africa.E'e ln Cameroun, the level of education was a main de-
terminant for good knowledge on HBV infection among
health-care workers of various background. This factor might
partially explain the relatively good knowledge reported in our
sample constituted solely of medical doctors. Poor knowl-
edge on HBV infection was also reported among medical
students entering the profession in Ethiopia highlighting the
need for early dedicated and adapted training courses.lo'11
Although routes of transmission were correctly identified,
other essential aspects such as the most at-risk period of
HBV acquisition and the ¡mportance of early administration
of the vaccine were only known by a minority of respon-
dents. Although these notions might also be challenging for
numerous medical doctors not familiar with HBV infection
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TÆre 2
Knowledge toward Hepatit¡s B in general practitioners compared with specialists (t',1 = 1271, Sênegal 2015
Gôneralpractltlonors Speclal¡sts(N= 45) (N= 82) P Total (N= 127)
HBV epidemiology
Route(s) of transmiss¡on for hepatit¡s B
Sexual iransmission
Yes
No
Contam¡nated blood
Yes
No
Mother-to-child transmission
Yes
No
HBV screening
Hepatit¡s B can be screened in asymptomatic patients
Yes
No/unknown
Rapid diagnostic tests can be used to screen hepatitis B
Yes
No/unknown
HBV vaccination
The hepatitis B vaccine can be safely administered to pregnant women
Yes
No/unknown
The hepatitis B vaccine can be safely administered to Newbom
Yes
No/unknown
The hepatitis B vaccine can lead to infedility
Yes/unknown
No
The hepatitis B vaccine can lead to neurolog¡cal disorders
Yes/unknown
No
HBVtreatment
ls there any existing etf¡cient treatment against chronic HBV infection?
Yes
No/unknown
ln case of treatment with antiviral therapy, what is the usual duration of such treatment?
Lifelong treatment
Other durat¡on/unknown
44 (e7.8)
1(2.2)
34 (75.6)
11 (24.4)
40 (88.e)
5 (1 1.1)
43 (95.6)
2(4.4)
I (17.8)
37 (82.2',)
6 (13.3)
3e (86.7)
21 (46.7)
24 (53.3)
27 (60.0)
18 (40.0)
32 V1.1)
13 (28.9)
12
33
(80.0)
(20.0)
(26.7)
(73.3)
79 (96.3)
3 (3.7)
74 (90.2\
B (e.8)
67 (81.7)
15 (18.3)
81 (sB.B)
1 (1.2)
22 (26.8)
60 (73.2)
I (e.8)
74 (eo.z)
34 (41.5)
48 (58.5)
107 (84.3)
20 (15.7)
124
3
14 (1 1 .0)
113 (8e.0)
65 (51.2)
62 (48.8)
0.65
0.02
0.28
0.36
0.25
0.53
0.45
0.04
0.12
0.94
0.31
4
123 (e6.8)
(3.2)
(85.0)
(15.0)
(80.3)
(1e.7)
(32.3)
(67.71
108
19
(e7.6)
(2.4)
(23.6)
(76.4)
30
97
61 (48.0)
66 (52.0)
7e (62.2)
48 (37.8)
47 (57.3)
35 (42.7)
44
38
(53.6)
(46.4)
36 66
16
102
25
29
53
41
86
(80.5)
(1e.5)
(35.4)
(64.6)
in developed countr¡es, these knowledge gaps are prob-
lematic in our study population as an important part of HBV
transmission occurs in early childhood or through mother-
to-child transmission in sub-Saharan Africa.
HBV vaccine is now part of the national immunization
program in Senegal. However, several challenges currently
limit its field efficacy including a limited coverage of lhe
target population and delays in the administration of thefirst
dose of vaccine that may not occur during the first 24 hours
after birth as recommended. Considering that half of med-
ical doctors in this sample believe that pregnancy is a
contra¡ndication to HBV vaccination and that this vaccine
should not be used in newborns, efforts are needed to ¡n-
form the medical community throughout sub-Saharan
Africa about the benefits of HBV screening of pregnant
women and vaccination of newborns right after birth, There
are growing concerns related to the knowledge of health-
care professionals toward prevention of mother-to-child
transmission of HBV in high-prevalence settings.l2'13 ¡n-
deed, screening of pregnant women is now of particular
interest as a recent clinical trial showed a significant
reduction of HBV mother-to-child transmission among
HBV-positive mother with high viral load receiving antiviral
therapy during pregnancy.l4 Medical doctors, specialists
or not, could play a key role to promote early HBV screen¡ng
and vaccination through programs designed to prevent
mother-to-child transmission.
Although the majority of participants were not directly in
charge of treating HBV infection, baseline knowledge on
available treatment opt¡ons is essential to inform and guide
patients if confronted with a positive HBV screening result.
lndeed, poor HBV knowledge among health-care profes-
sionals was reported to be a major barrier to linkage to HBV
care ¡n Burkina Faso.15 Lamivudine and tenofovir are two
nucleosidic reverse transcriptase inhibitors active aga¡nst
HBV replication that are now freely available for HIV-
infected persons in many African countr¡es. Although the
access to these drugs is currently not guaranteed for all
eligible HBV-infected patients, several initiatives are on-
going to expand their free access for this particular pop-
ulation. Although the majority of respondents were aware
that anti-HBV therapy was not systematically indicated in
the case of chronic HBV infection, only half of them identi-
fied HIV infection as a priority indication for HBV treatment.
This poor knowledge of treatment needs in the context of
HIV/HBV co¡nfection is particularly worrying as access to
anti-HBV therapy is free of charge for H|V-infected persons
and international as well as national guidelines clearly
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T¡sLr 3
Factors associatêd with a low knowledge score on hepatitis B ¡n medical doctors from Dakar, Saint-Louis, and Ziguinchor (N 
= 127),Senegal, 201 5
Univar¡at€ analys¡s Mult¡var¡able analys¡s
oR (95% CD OR (9570 Cl)
Age
< 40 years
> 40 years
Gender
Women
Men
City
Dakar
Saint-Louis
Ziguinchor
Medical practice
Specialist
General practitioner
Time since first medical certification
< 4 years
> 4 years
Lectures on HBV.
Yes
No
HBV screening proposedf
FrequenVsystematic
Never/rarely
Personal history of HBV screening
Yes
No
HBV vaccination status assessed+
Yes
No
Personal history of HBV vaccination
Yes
No
17/92
1 0/35
12/43
15/84
16n5
3/22
8/30
14/82
13/45
15/62
12t65
2/39
25/88
12/81
15/46
21 /101
6/25
1 9/88
6/27
1
1.8 (0.7-4.3)
1
1.8 (0.7-4.2)
1
0.6 (0.2-2.2)
1.3 (0.5-3.6)
1
2.0 (0.8-4.7)
0.7 (0.3-1.7)
7.3 (1.6-32.8)
1
2.8 (1.2-6.6)
1
0.8 (0.3-2.3)
1
1.0 (0.3-2.7)
1.1(0.4-2.9)
0.20
0.19
0.23
0.12
0.43
0.009
0.02
0.72
0.99
0.83
1
3.1(1.0-e.2)
1
1.7 (0.6-4.41
1
0.3 (0.1-1.5)
0.8 (0.3-2.5)
2.6 (1.0-7.3)
1
6.0 (1.4-26.4)
1
3.0 (1.1-8.2)
0.04
0.28
0.39
0.05
0.02
0.03
Cl - conlidenc€ intorval; HBV 
= 
hepat¡t¡s
. Pract¡t¡onôrs that attended at least one
B vlrus; OR 
= 
odd rat¡o; n/N 
= 
number ofpract¡tloners wlth å low knowledge score^otal number of pract¡tloneß tor a sp€c¡lic category.
lecture or othêr dldactlc ev€nt ded¡cat€d to HBV infection asìd€ thelr ¡nitlal m€dlcal training.
I ln your medical practice, do you propose lhe screening of HBV infect¡on to your pat¡ents?
+ ln case of a psdlatrlc pat¡ent, would you usually chsck his/her HBV vacc¡nation status?
recommend treatment of all HIV/HBV co-infected individu-
als independently of their CD4 cell counts.16
Older age, being a general practitioner (versus a spe-
cialist) and no prior history of continuing medical education
on HBV infectlon were associated with a lower knowledge
score. lnterventions to promote knowledge on HBV in-
fection such as dedicated courses or conferences should
be proposed and organized among medical doctors after
their initial medical training. These initiatives should not be
restricted to specialists but adapted to general practitioners
as they are expected to play a central role in HBV prevention
through the promotion and application of universal HBV
vacc¡nation and testing. The association reported here be-
tween poorer screening attitudes and low knowledge score
is in line with a previous survey conducted in a group of 240
health care and public health professionals in China.17
These results emphasize the importance of dedicated
training initiatives to promote universal screening of HBV
infection as recently advocated by the World Health orga-
nization (WHO).18
Self-reported practices of personal HBV screening and
vaccination were not associated with good knowledge on
HBV infection as previously reported among medical stu-
dents in Ethiopia.lo The declared rates of screening and
vaccination were relatively high among the responding med-
ical doctors desplte HBV vaccinat¡on not being mandatory
for health-care personnel in Senegal. Previous studies have
reported anti-HBV vaccination practices among health-care
workers in Africa but their results were quite contrasted. ln
several surveys conducted in West and Southern Africa,
hepatitis B vaccine coverage reported by health-care
professionals was close to what we observed in our sur-
vey, with rates of 64.5% in Nigeria and 67.9% in South
Africa.le'20 ln other contexts, particularly in East and Central
Africa, declared immunization coverage appeared to be
significantly lowerwith rates ranging from 4 .51o12.8%o.21-23
Health-care workers are highly exposed to health-care-
associated infections trough occupational exposures to
percutaneous injuries in sub-Saharan Africa.2a-26 WHO
estimated that 6,200 new HBV infections contracted by
health professionals occurred each year in this region of the
world.27 The optimal strategy to prevent such health-care-
assoc¡ated HBV infections in high-prevalence settings still
needs to be determined. lndeed, some authors have argued
that considering the particularly high proportion of adults
naturally protected against HBV infection, universal vacci-
nation of health-care workers was not a relevant strategy.2s
An alternatlve approach to universal vaccination would be to
implement a systemat¡c HBV screening and provide vacci-
nation only to those eligible never exposed to HBV. How-
ever, this "screen and vaccinate" strategy raises concerns
about acceptability, risk of stigma and needs feasibility
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studies. Previous studies from Tanzan¡a and Rwanda have
found poor HBV screening and vaccination uptake among
health-care workers despite them knowing that working
in he-alth-care settings increases their risk to acquire
HBV.21'2e ln our population, the natural history of HBV
infection as well as its clinical complications were relatively
well mastered, potentially explaining the good self-reported
practices of personal HBV screening and vaccination.
Nevertheless, more education about the drastic effects of
the virus is needed in health-care settings throughout sub-
Saharan Africa.
Limitations. The representativeness of our study sample
might have been distorted by a relatively low response rate in
Dakar compared with Saint-Louis and Ziguinchor. As a con-
sequence, specialists may have been over-represented
compared with general practitioners in Dakar. However, in
Saint-Louis and Ziguinchor all practitioners identified from the
public sector responded to the questionnaire; the proportion
of specialists was also high and not significantly different
compared with Dakar. General practitioners practicing in the
private sector were not represented. lt is however rather un-
likely that gaps reported in knowledge and attitudes toward
HBV of our population might be lower among general practi-
tioners outside the publ¡c health sector in Senegal. Other
clinical centers in Senegal from the private sector and outside
the three targeted cities are also currently managing HBV-
infected persons and might differ in terms of knowledge and
practices toward HBV infection. We estimate, however, they
represented a small number of practitioners at the time of the
survey.
We opted for a self-administered questionnaire, potentially
overestimating the true knowledge of respondents as they
mayhave been ableto consult sources of information on HBV
infection before filling in the form. To prevent this kind of
behaviors, participants were clearly informed about the
objectives and expected results of the study and the need
to honestly respond without any additional help. lt was
clearly stated that participants were not personally evaluated
and that questionnaires were collected and processed
anonymously.
Only medical doctors were included in this survey, Other
health-care professionals are likely to get involved in the
prevention and care of HBV-infected persons in Senegal.
Expanding knowledge, att¡tudes, and practices studies to
other caregivers is needed. ln particular, suryeys targeting
midwives and nurses should be conducted as they are in the
frontline for the prevention of mother-to-child transmission of
HBV infection trough screening and vaccination.
CONCLUSION
ln the Senegalese context of high prevalence of HBV
infection and shortages of hepatologists and infectious
diseases specialists, all medical practitioners are expected
to become involved in the prevention and care of HBV in-
fection. Although general knowledge related to risk factors
and potential complications of HBV infection was rela-
tively good among medical doctors in major urban settings,
efforts are needed to improve their knowledge on pre-
vention and care of HBV. As WHO now recommends HBV
testing of the general population in settings with HBV prev-
alence above 5%, screening practices, which seem to be
associated with low knowledge on HBV, need to be drasti-
cally improved. There ¡s an urgent need to inform and raise
awareness toward HBV prevention among medical practi-
tioners in Senegal, a country example where public health
efforts to control and eliminate HBV infection are possible
and urgently needed.
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Knowledge score items (N = 127)
L Epidemiology and natural history
1. According to you, hepat¡t¡s B is caused by which type of infectious agent:
Virus (1)'
Bacter¡a (0)
Unknown (0)
2. The evolution of hepatitis B can be:
Acute and/or chronic (1 )
Only acute (0)
Only chronic (0)
Unknown (0)
3. According to you, what is the prevalence of hepatitis B among the adult general population in West Africa
2-6% (0)
6-150/o (11
> 15% (0)
Unknown (0)
4. What (is) are the route(s) of transmission for hepatitis B
Sexual
Yes (1)
No (0)
Contam¡natêd blood
Yes (1)
No (0)
Airborne
Yes (0)
No (1)
Contaminated water
Yes (0)
No (1)
Mother to ch¡ld
Yes (1)
No (0)
5. The risk of developing a chronic hêpatitis B ¡s relatêd to th€ age of acquisition of hepat¡tis B?
Yes (1)
No (0)
Unknown (0)
6. Which ¡s the most "at risk" period in life for the acquisition of hepatitis B in Senegal
G-5 years (1)
5-15 years (0)
15-35 years (0)
> 35 years (0)
Unknown (0)
7. Among these factors, which one(s) is (are) associated with the acquisition of hepat¡tis B
Mult¡plê sêxual partners
Yes (1)
No (0)
Unknown (0)
lntravenous drug use
Yes (1)
No (0)
Unknown (0)
Tobacco use
Yes (0)
No (1)
Unknown (0)
Therapeutic abortion
Yes (0)
No (1)
Unknown (0)
ll. Clinical complications
B. According to you, which complication(s) can be related to a chronic hepat¡tis B
Liver cancer
Yes (1)
Unknown (0)
Diabetes
Yes (0)
No (1)
Unknown (0)
N (o/ol
124 (97.6)
2 (1.6)
1 (0.8)
(e.4)
(3e.4)
(40.e)
(10.2)
98 (77.21
1 (0.8)
20 (15.7)
I (6.3)
(s6.8)
(3.2)
(85.0)
(15.0)
12
50
52
13
123
4
108
19
16 02.6)
111(87.4)
2 (1.6)
125 (98.4)
1O7 (84.2\
20 (15.8)
53 (41.7)
5e (46.5)
15 (1 1 .8)
1e (15.0)
7 (5.5)
55 (43.3)
14 (11 .0)
32 (25.2)
119 (e3.7)
0 (0.0)
I (6.3)
2 (1.6)
56 (44.1)
6e (54.3)
13 (10,2)
43 (33.9)
71 (56.0)
N ("/")
125 (98.4)
2 (1.6)
123 (e6.8)
1 (0.8)
3 (2.4)
(1.6)
(41.71
(56.7)
2
53
72
(cont¡nued)
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Dementia
Yes (0)
No (1)
Unknown (0)
Lung cancer
Yes (0)
No (1)
Unknown (0)
St¡llb¡rth
Yes (0)
No (1)
Unknown (0)
Liver cirrhosis
Yes (1)
Unknown (0)
Esophageal varicose
Yes
No
Unknown (0)
Hepatocellular impairment
Yes (1)
Unknown (0)
9. Which of the following risk(s) factor(s) are associated with liver cancer
Hepat¡tis B
Yes (1)
Unknown (0)
Hepatitis C
Yes (1)
No (0)
Unknown (0)
Hepatitis A
Yes (0)
No (1)
Unknown (0)
Alcohol
Yes (1)
No (0)
Unknown (0)
Tobacco
Yes (0)
No (1)
Unknown (0)
lll. HBVscreening
10. Hepatitis B can be screened in asymptomatlc patients
Yes (1)
No (0.0)
Unknown (0)
1 1 . Which kind of tests can be used to screen hepatitis B
Serological assay
Yes (1)
No (0)
Unknown (0)
Rapid diagnostic tests
Yes (1)
No (0)
Unknown (0)
PCR quantification of hepatitis B
Yes (0)
No (1)
Unknown (0)
12. Which test(s) should bo pad of thê initial assessment in case of first positive test for hepatitis B
ALT
Yes (l)
No (0)
Unknown (0)
AST
Yes (1)
No (0)
Unknown (0)
5 (4.0)
48
74
(37.8)
(58.3)
I
50
69
(6.3)
(3e.4)
(54.3)
20 (15.7)
36 (28.4)
71 (55.9)
124 (97.6)
3 (2.41
95 (74.8)
7 (5.5)
25 (1e.7)
(e2.e)
(7.1)
118
o
102
4
21
(80.3)
(3.2)
(16.5)
I (6.3)
44 (34.6)
75 (59.1)
110 (86.6)
4 (3.1)
13 (10.2)
31(24.4)
28 (22.11
68 (53.5)
N (o/o)
124 (97.6)
0 (0.0)
3(2.4)
0
(e8.4)
(0.0)
2 (1.6)
30 (23.6)
25 (1e.7)
72(56.7)
34 (26.8)
20 (15.7)
73 (57.5)
121 (95.3)
0 (0.0)
6 (4.7)
117 (92.1)
0 (0.0)
10 (7.9)
126 (99.2)
1 (0.8)
25
(continued)
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Repeated serology at six months
Yes (1)
No (0)
Unknown (0)
Abdominal ultrasounds
Yes (1)
No (0)
Unknown (0)
PCR quantification of hepatitis B
Yes (1)
No (0)
Unknown (0)
lV. HBV vaccination
13. The Hepat¡t¡s B vaccine can be safely administered to:
Every patient without restriction
Yes (1)
No (0)
Unknown (0)
Young ch¡ldren
Yes (1)
No (0)
Unknown (0)
Prognant women
Yes (1)
No (0)
Newbom
Yes (1)
No (0)
Unknown (0)
1 4. The Hepatitis B vaccine has a proven efficacy
Yes (1)
No (0)
Unknown (0)
15. The Hepatitis B vaccinê can lead to infertility
Yes (0)
No (1)
Unknown (0)
16. Thê Hepatitis B vaccine can lead to nêurological disorders
Yes (0)
No (1)
Unknown (0)
17. How many injections are needed to complete the HBV vacc¡nation in children
3 injections (1)
Others (0)
Unknown (0)
18. ln which period of time does the HBV vaccination need to be completed in children
3 months (0)
6 months (1)
12 months (0)
24 months (0)
Unknown (0)
19. How many inject¡ons are needed to complete the HBV vaccination in adults
3 injections (1)
Others (0)
Unknown (0)
20. ln which period of time does the HBV vaccination need to be completed ¡n adults
3 months (0)
6 months (1)
12 months (0)
24 months (0)
Unknown (0)
V. HBV treatment
21. ls there any existing effic¡ent treatment against chronic HBV infection?
Yes (1)
No (0)
Unknown (0)
80 (63.0)
I (6.3)
39 (30.7)
e3 (73.2)
13 (1 0.2)
21(16.5)
90 (70.8)
s (7.1)
28 (22.11
68 (53.5)
31(24.41
28 (22.11
e1 (71.6)
1 (0.8)
35 (27,6)
14 (11.0)
1 13 (89.0)
65 (51.2)
13 (10.2)
49 (38.6)
121 (95.3)
1 (0.8)
5 (4.0)
0 (0.0)
66 (52.0)
61 (48.0)
4 (3.21
48 (37.8)
75 (59.1)
79 (62.2)
27 (21.3',)
21(16.5)
2s (19.7)
13 (10.2)
35 (27.6)
12 (e.4)
42 (33.1)
81 (63.8)
28 (22.0)
18 ('t4.2)
27 (21.3)
27 (21.3)
23 (18.1)
5 (4.0)
45 (35.4)
N (o/o)
102 (80.3)
15(11.8)
10 (7.9)
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22. Which of the following treatment(s) have a proven efficacy againsi HBV infection
lnterferon?
Yes (1)
No (0)
Unknown (0)
Ribav¡rinê
Yes (1)
No (0)
Unknown (0)
Lamivudine
Yes (1)
No (0)
Unknown (0)
Tenofovir
Yes (1)
No (0)
Unknown (0)
Zidovudine
Yes (0)
No (1)
Unknown (0)
Trad¡tional mêdicine
Yes (0)
No (1)
Unknown (0)
Surgery
Yes (0)
No (1)
Unknown (0)
Penicillin
Yes (0)
No (1)
Unknown (0)
23. ln case of chronic HBV infection, in which situation(s) is a treatment needed?
ln any case, with a confirmed chronic HBV infection
Yes (0)
No (1)
Unknown (0)
According to the
Yes (1)
No (0)
Unknown (0)
ln cas6 of HIV coinfection, regardless of the immunological status
Yes {1)
No (0)
Unknown (0)
24. ln case of treatment w¡th ant¡viral therapy, what is thê usual duration of such treatment?
Lifelong treatment (1)
Limited duration (0)
Unknown (0)
96 (75.6)
20 (15.7)
11(8.7)
20 (15.7)
96 (75.6)
11 (8.7)
65 (51.2)
51 (40.2)
11 (8.7)
73 (57.5)
43 (33.e)
11(8.7)
(8.7)
1 (0.8)
1 15 (90.5)
11 (8.7)
(7.1)
(84.21
I
07
11
4(3.2)
112
11
(88.2)
(8.7)
0
116
11
19
104
4
101
22
4
(0.0)
level of liver injuries (fibrosis/cirhos¡s) combined with biological criter¡a (liver enzymes and HVB viral load)
68 (53.5)
55 (43.3)
4(3.2)
(e1.3)
(8,7)
(14.s)
(e1.e)
(3.2)
c/e.5)
(17.3)
(3.2)
(32.3)
(65.3)
(2.4',)
41
56
3
' Eåch ¡tsm ls followed by ¡ts attrlbuted points (0) or (1).
